NKG2A, a New Kid on the Immune Checkpoint Block.

Abstract

One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine targeting of a novel immune checkpoint, NKG2A, that can be expressed on both NK cells and on CD8⁺ T cells, either combined with a tumor-targeting antibody or with a tumor-specific vaccine.